Meglumine Antimonate
drugOn this page
Also known as GlucantimGlucantimeMeglumine antimoniateN-methylglucamine antimonateN-methylglucamine antimoniateglucatimN-methylglucomine antimoniateANTIMONIATE_DE_MEGLUMINEglucantime stibenic acidMeglumine Antimoniate
Summary
Meglumine Antimonate (CHEMBL239129) is a phase-3 clinical-stage small molecule (ATC P01CB01); indicated across 5 conditions including cutaneous leishmaniasis and leishmaniasis.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Small molecule
- ATC class: P01CB01
- Indications: 5 conditions
- Clinical trials: 18
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL239129 |
| Name | Meglumine Antimonate |
| Type | Small molecule |
| Max phase | 3 |
| ATC | P01CB01 |
Also known as: Glucantim, Glucantime, Meglumine antimonate, Meglumine antimoniate, N-methylglucamine antimonate, meglumine antimoniate, glucantime, N-methylglucamine antimoniate, glucatim, N-methylglucomine antimoniate, ANTIMONIATE_DE_MEGLUMINE, glucantime stibenic acid
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| cutaneous leishmaniasis | 3 | MONDO:0005446 | EFO:0005046 |
| leishmaniasis | 3 | MONDO:0011989 | EFO:0005044 |
| trypanosomiasis | 3 | MONDO:0000940 | DOID:10113 |
| bipolar disorder | 3 | MONDO:0004985 | MONDO:0004985 |
| mucocutaneous leishmaniasis | 2 | MONDO:0005859 | EFO:0007379 |
Clinical trials
Total trials: 18.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 6 |
| PHASE3 | 5 |
| PHASE4 | 3 |
| PHASE2/PHASE3 | 3 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00317980 | PHASE4 | COMPLETED | Safety and Efficacy of Low-Dose Pentavalent Antimony for Treatment of Cutaneous Leishmaniasis |
| NCT00818818 | PHASE4 | COMPLETED | Low-dose Pentavalent Antimony Treatment of Cutaneous Leishmaniasis in Old Age Patients |
| NCT01032187 | PHASE4 | COMPLETED | Amphotericin B to Treat Visceral Leishmaniasis in Brazilian Children |
| NCT00317629 | PHASE3 | TERMINATED | Controlled Nitric Oxide Releasing Patch Versus Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis |
| NCT00487253 | PHASE3 | UNKNOWN | Oral Miltefosine for the Treatment of Pediatric Cutaneous Leishmaniasis in Colombia |
| NCT01301924 | PHASE2/PHASE3 | COMPLETED | Comparison of Standard and Alternative Antimonial Dosage in Patients With American Cutaneous Leishmaniasis |
| NCT01301937 | PHASE2/PHASE3 | UNKNOWN | Low Antimonial Dosage in American Mucosal Leishmaniasis |
| NCT01464242 | PHASE2/PHASE3 | COMPLETED | Add-on Study of Pentoxifylline in Cutaneous Leishmaniasis |
| NCT01953744 | PHASE3 | TERMINATED | High Dose Fluconazole in Cutaneous Leishmaniasis in Bahia and Manaus |
| NCT04340128 | PHASE3 | COMPLETED | Efficacy of Intra-lesional Injections of Glucantime Once a Week or Twice a Week in the Treatment of Anthroponotic Cutaneous Leishmaniasis (ACL) |
| NCT04515186 | PHASE3 | COMPLETED | Combination, Miltefosine Monotherapy for Cutaneous Leishmaniasis in New World |
| NCT02530697 | PHASE2 | ACTIVE_NOT_RECRUITING | The Association of Miltefosine and Pentoxifylline to Treat Mucosal and Cutaneous Leishmaniasis: A Clinical Trial in Brazil |
| NCT00004755 | PHASE2 | COMPLETED | Allopurinol, Glucantime, or Allopurinol/Glucantime for Cutaneous Leishmaniasis in Brazil |
| NCT00537953 | PHASE2 | UNKNOWN | Short Course of Miltefosine and Antimony to Treat Cutaneous Leishmaniasis in Bolivia |
| NCT00973128 | PHASE2 | COMPLETED | Reduced Doses of Antimony Plus Ranulocyte Monocyte Colony Stimulating Factor (GM-CSF) for Cutaneous Leishmaniasis |
| NCT03084952 | PHASE2 | UNKNOWN | Phase 2 Trial to Evaluate 18-Methoxycoronaridine Efficacy, Safety and Tolerability in Cutaneous Leishmaniasis Patients |
| NCT03294161 | PHASE2 | COMPLETED | Fourth-generation Immucillin Derivative DI4G Associated Therapy in Cutaneous Leishmaniasis |
| NCT00480883 | Not specified | COMPLETED | Treatment of Cutaneous Leishmaniasis With Meglumine Antimoniate Versus Meglumine Antimoniate and Allopurinol |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).